<html>
<head>
<title>PubMed</title>
<meta http-equiv="Content-Type" content="text/html; charset=iso-8859-1">
<link rel="stylesheet" href="../journal_club.js" type="text/css">
<script language="JavaScript">
<!--
function MM_openBrWindow(theURL,winName,features) { //v2.0
  window.open(theURL,winName,features);
}
//-->
</script>
</head>

<body bgcolor="B6B6B6">
<table width="777" border="0" cellpadding="0" cellspacing="0" bgcolor="880000" align="center">
  <tr> 
    <td height="64" valign="top" colspan="2"> 
      <table width="100%" border="0" cellpadding="0" cellspacing="0" bgcolor="000000" align="center">
        <tr> 
          <td width="750" height="50" valign="middle"> 
            <div align="center"> 
              <p><font color="#FFFFFF"><a name="Top"></a><img src="../Assets/ABMtitle.gif" width="660" height="50"></font></p>
            </div>
          </td>
        </tr>
      </table>
    </td>
  </tr>
  <tr> 
    <td height="37" width="54"></td>
    <td valign="top" width="723"> 
      <table width="100%" border="0" cellpadding="0" cellspacing="0">
        <tr> 
          <td width="723" height="37"><a href="SS_ABM.html"><img src="../Assets/PM1.gif" width="165" height="37" align="baseline" name="Short_Summary" border="0"></a><a href="ACP_ABM.html"><img src="../Assets/PM2.gif" width="142" height="37" name="ACP" border="0"></a><a href="CE_ABM.html"><img src="../Assets/PM3.gif" width="140" height="37" name="Clinical_Evidence" border="0"></a><a href="JNC6_ABM.html"><img src="../Assets/PM4.gif" width="77" height="37" name="JNC_VI" border="0"></a><a href="PM_ABM.html"><img src="../Assets/PM5.gif" width="78" height="37" name="PubMed" border="0"></a><a href="VA_ABM.html"><img src="../Assets/PM6.gif" width="121" height="37" border="0"></a></td>
        </tr>
      </table>
    </td>
  </tr>
  <tr> 
    <td height="50"></td>
    <td valign="top"> 
      <table width="100%" border="0" cellpadding="0" cellspacing="0">
        <tr> 
          <td width="723" height="38"><img src="../Assets/PMheader.gif" width="330" height="50" align="baseline"><img src="../Assets/PMheader2.gif" width="393" height="50" align="baseline"></td>
        </tr>
      </table>
    </td>
  </tr>
  <tr> 
    <td height="469"></td>
    <td valign="middle" bgcolor="#FFFFCC"> 
      <div align="center"><br>
        <table width="88%" border="0" height="508">
          <tr>
            <td bgcolor="#FFFFCC"> 
              <div align="center"> 
                <p align="left"><font face="Verdana, Arial, Helvetica, sans-serif" size="2" color="663333"><b><a name="ALLHAT"></a>The 
                  ALLHAT Officers and Coordinators for the ALLHAT Collaborative 
                  Research Group. Major cardiovascular events in hypertensive 
                  patients randomized to doxazosin vs chlorthalidone: the antihypertensive 
                  and lipid-lowering treatment to prevent heart attack trial (ALLHAT). 
                  JAMA 2000;283:1967&#150;1975.</b></font></p>
                <p align="left"> </p>
                <p align="left"><font face="Verdana, Arial, Helvetica, sans-serif" size="2" color="663333"><b>Abstract</b>:<br>
                  </font><font face="Verdana, Arial, Helvetica, sans-serif" size="2" color="663333">CONTEXT: 
                  Hypertension is associated with a significantly increased risk 
                  of morbidity and mortality. Only diuretics and beta-blockers 
                  have been shown to reduce this risk in long-term clinical trials. 
                  Whether newer antihypertensive agents reduce the incidence of 
                  cardiovascular disease (CVD) is unknown. OBJECTIVE: To compare 
                  the effect of doxazosin, an alpha-blocker, with chlorthalidone, 
                  a diuretic, on incidence of CVD in patients with hypertension 
                  as part of a study of 4 types of antihypertensive drugs: chlorthalidone, 
                  doxazosin, amlodipine, and lisinopril. DESIGN: Randomized, double-blind, 
                  active-controlled clinical trial, the Antihypertensive and Lipid-Lowering 
                  Treatment to Prevent Heart Attack Trial, initiated in February 
                  1994. In January 2000, after an interim analysis, an independent 
                  data review committee recommended discontinuing the doxazosin 
                  treatment arm based on comparisons with chlorthalidone. Therefore, 
                  outcomes data presented herein reflect follow-up through December 
                  1999. SETTING: A total of 625 centers in the United States and 
                  Canada. PARTICIPANTS: A total of 24,335 patients (aged &gt; 
                  or = 55 years) with hypertension and at least 1 other coronary 
                  heart disease (CHD) risk factor who received either doxazosin 
                  or chlorthalidone. INTERVENTIONS: Participants were randomly 
                  assigned to receive chlorthalidone, 12.5 to 25 mg/d (n=15,268), 
                  or doxazosin, 2 to 8 mg/d (n=9067), for a planned follow-up 
                  of 4 to 8 years. MAIN OUTCOME MEASURES: The primary outcome 
                  measure was fatal CHD or nonfatal myocardial infarction (MI), 
                  analyzed by intent to treat; secondary outcome measures included 
                  all-cause mortality, stroke, and combined CVD (CHD death, nonfatal 
                  MI, stroke, angina, coronary revascularization, congestive heart 
                  failure [CHF], and peripheral arterial disease); compared by 
                  the chlorthalidone group vs the doxazosin group. RESULTS: Median 
                  follow-up was 3.3 years. A total of 365 patients in the doxazosin 
                  group and 608 in the chlorthalidone group had fatal CHD or nonfatal 
                  MI, with no difference in risk between the groups (relative 
                  risk [RR], 1.03; 95% confidence interval [CI], 0.90-1.17; P=.71). 
                  Total mortality did not differ between the doxazosin and chlorthalidone 
                  arms (4-year rates, 9.62% and 9.08%, respectively; RR, 1.03; 
                  95% CI, 0.90-1.15; P=.56.) The doxazosin arm, compared with 
                  the chlorthalidone arm, had a higher risk of stroke (RR, 1.19; 
                  95% CI, 1.01-1.40; P=.04) and combined CVD (4-year rates, 25.45% 
                  vs 21.76%; RR, 1.25; 95% CI, 1.17-1.33; P&lt;.001). Considered 
                  separately, CHF risk was doubled (4-year rates, 8.13% vs 4.45%; 
                  RR, 2.04; 95% CI, 1.79-2.32; P&lt;.001); RRs for angina, coronary 
                  revascularization, and peripheral arterial disease were 1.16 
                  (P&lt;.001), 1.15 (P=.05), and 1.07 (P=.50), respectively. CONCLUSION: 
                  Our data indicate that compared with doxazosin, chlorthalidone 
                  yields essentially equal risk of CHD death/nonfatal MI but significantly 
                  reduces the risk of combined CVD events, particularly CHF, in 
                  high-risk hypertensive patients. [<a href="#" onClick="MM_openBrWindow('Indiv_ALLHAT2000.html','','status=yes,scrollbars=yes,resizable=yes,width=650,height=500')">See 
                  ACP Summary</a>]</font></p>
              </div>
              <p class="BEsection" align="right"><a href="#Top"><img src="../Assets/Top.gif" width="76" height="37" border="0"></a></p>
              </td>
          </tr>
        </table>
        
      </div>
    </td>
        </tr>
  <tr> 
    <td height="28"></td>
    <td valign="top"> 
      <table width="100%" border="0" cellpadding="0" cellspacing="0" bgcolor="#55C6C6">
        <tr> 
          <td width="723" height="28" bgcolor="ff4d4a"> 
           
          </td>
        </tr>
      </table>
    </td>
  </tr>
</table>
</body>
</html>
